Incorporating the lymphocyte-C-reactive protein ratio into risk stratification for intrahepatic cholangiocarcinoma

A modified TNM (mTNM)system incorporating LCR was proposed.</p> <p>Low LCR was an independent prognostic factor for both overall survival (OS) and recurrence-free survival (RFS) by multivariable analysis.

Median OS and RFS times were 43.2 and 12.8 months. Patients were stratified into 5 subgroups according to the mTNM staging system: group 1 (<i>n</i> = 67): stage I, LCR > 6000, group 2 (<i>n</i> = 50): stage I, LCR ≤ 6000, group 3 (<i>n</i> = 49): stage II, LCR > 6000, group 4 (<i>n</i>= 49): stage II, LCR ≤ 6000, and group 5 (<i>n</i> = 33): stage III with any LCR. Survival overlaps occurred between groups 2 and 3 (median OS: 49.4 vs 36.6 months; median RFS: 16.2 vs 13.8 months, <i>p</i> > 0.05).